NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis $13.38 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$13.39 +0.01 (+0.07%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Contineum Therapeutics Stock (NASDAQ:CTNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Contineum Therapeutics alerts:Sign Up Key Stats Today's Range$12.94▼$13.8650-Day Range$11.50▼$17.5752-Week Range$8.60▼$17.78Volume885,589 shsAverage Volume820,651 shsMarket Capitalization$503.37 millionP/E RatioN/ADividend YieldN/APrice Target$22.17Consensus RatingModerate Buy Company Overview Contineum Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing medicines for diseases of the central nervous system. The company’s research is centered on therapeutics designed to promote remyelination, the repair of damaged myelin that supports nerve function, and to address neuroinflammation and other mechanisms involved in neurological disorders. Contineum’s pipeline includes PIPE-307, an oral, selective M1 muscarinic receptor antagonist being investigated for its potential to promote remyelination in multiple sclerosis. The company is also developing PIPE-791, an oral small-molecule lysophosphatidic acid receptor 1 antagonist intended for central nervous system and fibrotic diseases. Its programs are based on research into biological pathways that may contribute to nerve damage, impaired repair and disease progression. The company was formerly known as Pipeline Therapeutics and is based in San Diego, California. Contineum is conducting clinical development through studies involving patients with neurological and other serious diseases, although specific geographic coverage and leadership details may change as the company advances its programs.AI Generated. May Contain Errors. Read More Contineum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreCTNM MarketRank™: Contineum Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 446th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingContineum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialContineum Therapeutics has a consensus price target of $22.17, representing about 65.7% upside from its current price of $13.38.Amount of Analyst CoverageContineum Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Contineum Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Contineum Therapeutics are expected to grow in the coming year, from ($1.68) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Contineum Therapeutics is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Contineum Therapeutics is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContineum Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Contineum Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.85% of the float of Contineum Therapeutics has been sold short.Short Interest Ratio / Days to CoverContineum Therapeutics has a short interest ratio ("days to cover") of 3.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Contineum Therapeutics has recently increased by 25.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContineum Therapeutics does not currently pay a dividend.Dividend GrowthContineum Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.53 News SentimentContineum Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Contineum Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for CTNM on MarketBeat in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.90% of the stock of Contineum Therapeutics is held by insiders.Percentage Held by InstitutionsContineum Therapeutics has minimal institutional ownership at this time.Read more about Contineum Therapeutics' insider trading history. Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTNM Stock News HeadlinesContineum Therapeutics, Inc. (NASDAQ:CTNM) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesOctober 8, 2026 | americanbankingnews.comAdherex Technologies (NASDAQ:FENC) vs. Contineum Therapeutics (NASDAQ:CTNM) Critical ContrastOctober 5, 2026 | americanbankingnews.comA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, and predictions. He argues a simpler approach can work just as well. His free report, The Simple Path To Success With Options, breaks down a repeatable trade setup, common rookie mistakes, and step-by-step blueprints designed to cut through market noise. No complex charts. No guesswork. Just a straightforward setup anyone can learn. | TradeWins (Ad)Contineum Therapeutics (NASDAQ:CTNM) versus Theravance Biopharma (NASDAQ:TBPH) Critical AnalysisOctober 2, 2026 | americanbankingnews.comContineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTradingSeptember 29, 2026 | theglobeandmail.comJ&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?September 24, 2026 | insidermonkey.comRBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)September 23, 2026 | theglobeandmail.comContineum Therapeutics Inc. - Ordinary Shares - Class ASeptember 22, 2026 | money.usnews.comSee More Headlines CTNM Stock Analysis - Frequently Asked Questions How have CTNM shares performed this year? Contineum Therapeutics' stock was trading at $11.43 on January 1st, 2026. Since then, CTNM stock has increased by 17.1% and is now trading at $13.38. How were Contineum Therapeutics' earnings last quarter? Contineum Therapeutics, Inc. (NASDAQ:CTNM) released its quarterly earnings results on Thursday, July, 30th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $117 million in an initial public offering on Friday, April 5th 2024. The company issued 6,875,000 shares at $16.00-$18.00 per share. How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Contineum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Contineum Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings7/30/2026Today10/11/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CTNM's financial health is in the Green zone, according to TradeSmith. CTNM has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CTNM Previous SymbolNASDAQ:CTNM CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees51Year Founded2017Price Target and Rating Average Price Target for Contineum Therapeutics$22.17 High Price Target$28.00 Low Price Target$17.00 Potential Upside/Downside+65.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-24.73% Return on Assets-23.51% Debt Debt-to-Equity RatioN/A Current Ratio37.17 Quick Ratio37.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.99 per share Price / Book1.91Miscellaneous Outstanding Shares37,621,000Free Float34,649,000Market Cap$503.37 million OptionableN/A Beta0.86 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CTNM) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredFive Seats Could Shift Washington’s DirectionDemocrats need just five more seats to flip House control, with forecasts giving them a 61% to 85% chance ahea...USA Capital Gold | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
